newsfilter
← Latest News
Business Wire·

The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced positive topline results for the ORION-9 Phase 3 clinical study in patients with Heterozygous Familial Hypercholesterolemia (HeFH). ORION-9 met all primary and secondary endpoints, and inclisiran demonstrated durable and potent efficacy and was well-tolerated with excellent safety that was generally well-balanced between the treatment groups. Furthermore, there were no treatment-related liver or renal laboratory abnormalities.